Hana Itani PhD, EMBA, FAHA, FASN

As a Principal Scientist at Regeneron, Hana Itani leverages her EMBA and Ph.D. training in molecular and cellular biology to drive the pre-clinical drug discovery for renal and cardiovascular disease. She has 15 years of experience in inflammation-mediated cardiovascular and kidney disease, CKD, and hypertension research, with a strong publication record and a track record of securing research funding from NIH, AHA, ASN, and AUB. She is passionate about mentoring and developing team members at all levels, from medical to undergraduate and graduate students, and promoting diversity, equity, and inclusion in the scientific community.

In her current role, She is responsible for drug target nomination and validation, developing and characterizing translatable models of kidney disease, and designing and interpreting pre-critical experiments for project progression. She collaborates with experienced clinical scientists and program directors to align the drug discovery strategy with unmet medical needs. She is skilled in communication, as evidenced by award-winning oral and poster presentations at national conferences and events, and experienced in writing, with 34 high-quality peer-reviewed publications. She is adept at enhancing the drug discovery process, leading teams, and fostering a culture of innovation, continuous learning, and collaboration to drive scientific excellence and achieve company goals.